A good year ago, Medigene acquired Trianta, a spin-off from the Helmholtz Zentrum München, taking on not only three innovative platforms for the development of anti-cancer immunotherapies, but also Prof. Dolores Schendel and her entire team. Since then, the most advanced platform, a personalized dendritic cell vaccine, has made significant progress. In March this year, the first company-sponsored Phase I/II clinical trial was initiated in acute myeloid leukaemia (AML). Moreover, Prof. Schendel presented positive interim results from an ongoing academic trial in various cancer indications at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, USA. Most notably, four patients with stage IV glioblastoma, who have been vaccinated for 11 to 16 months, are all in complete remission. All patients tolerated the vaccination well. ‘These anecdotal data further support the vaccine’s potential,’ comments Dr Stefanie Possekel, Director at Ascenion. ‘I am very much impressed with Prof. Schendel’s energy and dedication, and that of the whole Medigene team progressing the clinical studies. They are truly committed to making new immunotherapies available to patients who currently have no effective treatment option.’
Find further information at: <link http: www.medigene.com presse-investoren news pressemitteilungen clinical-data-of-medigenes-dendritic-cell-dc-vaccines-pres external-link-new-window>www.medigene.com/presse-investoren/news/pressemitteilungen/clinical-data-of-medigenes-dendritic-cell-dc-vaccines-pres
